| [1] |
Zhu P, Liao W, Zhang WG, et al. A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic or open liver resection for patients with BCLC stage 0-A hepatocellular carcinoma[J]. Ann Surg, 2023, 277(1):e103-111.
|
| [2] |
Goh EL, Chidambaram S, Ma S. Laparoscopic vs open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a meta-analysis of the long-term survival outcomes[J]. Int J Surg,2018(50):35-42.
|
| [3] |
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1):25-34.
|
| [4] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
|
| [5] |
Finn RS, Ikeda M, Zhu AX, et al. PhaseⅠb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26):2960-2970.
|
| [6] |
Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2021, 39(27):2991-3001.
|
| [7] |
Akce M, El-Rayes BF, Bekaii-Saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update[J]. Therap Adv Gastroenterol, 2022(15):17562848221086126.
|
| [8] |
Zhang B, Zhang B, Zhang Z, et al. 42,573 cases of hepatectomy in China: a multicenter retrospective investigation[J]. Sci China Life Sci, 2018, 61(6):660-670.
|
| [9] |
Zhang XP, Gao YZ, Chen ZH, et al. An Eastern hepatobiliary surgery hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study[J]. Hepatology, 2019, 69(5):2076-2090.
|
| [10] |
Kamiyama T, Kakisaka T, Orimo T, et al. Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus[J]. World J Hepatol, 2017, 9(36):1296-1304.
|
| [11] |
Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase Ⅲ RESORCE trial[J]. J Hepatol, 2018, 69(2):353-358.
|
| [12] |
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6):618-632.
|
| [13] |
Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J]. JAMA, 2012, 308(18):1906-1914.
|
| [14] |
Huang G, Lai EC, Lau WY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels[J]. Ann Surg, 2013, 257(3):490-505.
|
| [15] |
Wang Z, Peng Y, Hu J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients[J].Ann Surg, 2020, 271(3):534-541.
|
| [16] |
Chan A, Zhang WY, Chok K, et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: a changing paradigm in modulation of future liver remnant before major hepatectomy[J]. Ann Surg, 2021, 273(5):957-965.
|
| [17] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022版)[J]. 中华消化外科杂志, 2022, 21(2):143-168.
|
| [18] |
Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment[J]. N Engl J Med, 2018, 379(18):1754-1765.
|
| [19] |
Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4):223-238.
|
| [20] |
Chin RI, Chen K, Usmani A, et al. Detection of solid tumor molecular residual disease (MRD) using circulating tumor DNA (ctDNA)[J]. Mol Diagn Ther, 2019, 23(3):311-331.
|
| [21] |
Cucchetti A, Zhong J, Berhane S, et al. The chances of hepatic resection curing hepatocellular carcinoma[J]. J Hepatol, 2020, 72(4): 711-717.
|
| [22] |
Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China[J]. JAMA Surg, 2019, 154(3):209-217.
|
| [23] |
Colecchia A, Schiumerini R, Cucchetti A, et al. Prognostic factors for hepatocellular carcinoma recurrence[J]. World J Gastroenterol, 2014, 20(20):5935-5950.
|
| [24] |
Hasegawa K, Kokudo N, Imamura H, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma[J]. Ann Surg, 2005, 242(2):252-259.
|